Lyrica

Fibromyalgia

Neuropathic Pain

Lyrica Resources

Resources for patients

Consumer information

Contains important product information including warnings, precautions, interactions, and dosing.

Viatris original brand LYRICA

Tips and tools to help your patients receive Viatris original brand LYRICA, as well as information about their medication and health.

Some insurers limit full-cost coverage for higher-cost interchangeable drugs to patients who meet certain criteria and in some cases, documentation from the prescriber is required. There is a possibility that the patient may need to contribute out-of-pocket where those conditions are not met.

Patient brochure

Resources for healthcare professionals

Guidelines from Diabetes Canada

Access the latest version of the Diabetes Canada Clinical Practice Guidelines, which includes valuable information on diabetic peripheral neuropathy. These guidelines are available to help orient your treatment decisions.

Diagnosing neuropathic pain (NeP)
In the diagnosis of NeP, the Self-completed Leeds Assessment of Neuropathic Signs and Symptoms (S-LANSS) questionnaire based on sensory descriptors and sensory examination has been shown to be a valid and reliable discriminator of NeP.

Dose card

Safety Information

Indications and clinical use:

LYRICA (pregabalin) is indicated for the:

  • Management of neuropathic pain associated with:
  • diabetic peripheral neuropathy
  • postherpetic neuralgia
  • spinal cord injury
  • Management of pain associated with fibromyalgia; efficacy for up to 6 months was demonstrated in a placebo-controlled trial in patients who had initially responded to LYRICA during a 6-week open-label phase

Not indicated in children.

Geriatrics (>65 years of age): dose reduction required due to age-related decreased renal function.

Relevant warnings and precautions:

  • Angioedema, including reports of life-threatening angioedema
  • history of angioedema/related events
  • other drugs associated with angioedema (e.g., ACE inhibitors)
  • Peripheral edema with increased incidence in combination with thiazolidinedione antidiabetic agents
  • Hypersensitivity
  • Renal failure; caution in renal impairment
  • Tumorigenic potential
  • Vision-related adverse events (blurry vision, diplopia)
  • Congestive heart failure
  • Serious skin reactions
  • Lower gastrointestinal tract related events
  • Weight gain
  • Dizziness and somnolence
  • Avoid abrupt or rapid discontinuation
  • Encephalopathy; caution in elderly with age-related compromised renal function and patients with kidney disease or risk factors for renal failure
  • Monitor for suicidal behaviour and ideation
  • Possible effects on male fertility
  • Pregnant patients should enroll in the North American Antiepileptic Drug (NAAED) pregnancy registry
  • Creatinine kinase elevations and rhabdomyolysis
  • Decreased platelets
  • PR interval prolongation

For more information:

Please consult the Product Monograph for important information relating to adverse reactions, drug interactions, and dosing information (including dose adjustments in renal impairment) which have not been discussed in this piece. The Product Monograph is also available by calling 1-800-463-6001.